GlucoTrack Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved two key proposals for stock issuance related to an ELOC agreement and bridge financing, both in compliance with NASDAQ rules. A quorum was present, and all proposals passed with the required votes. Final results will be filed with the SEC.
-
The meeting saw the election of six directors, approval of executive compensation, auditor ratification, amendments for potential reverse stock splits, and warrant inducement proposals. All items received the necessary votes and will be reported to the SEC.
-
Three key proposals were presented: share issuances to an investor, warrant exercise approval, and auditor ratification. All proposals received the required stockholder approval, with final results to be filed with the SEC.
Fiscal Year 2025
-
A reconvened special meeting aimed to approve a major stock issuance but was permanently adjourned due to lack of quorum, with only 17.6% of eligible votes represented.
-
A fully implantable, three-year continuous blood glucose monitor is being developed, targeting a 3 million patient U.S. market segment underserved by current wearables. Clinical trials are underway in Australia and planned for the U.S., with commercial approval aimed for late 2028.